Aurobindo Pharma Subsidiary Eugia Pharma Receives USFDA Approval For Budesonide Inhalation Suspension

Aurobindo Pharma Subsidiary Eugia Pharma Receives USFDA Approval For Budesonide Inhalation Suspension

The product is expected to be launched in FY25. The approved product has an estimated market size of US dollar 226.4 million for the twelve months ending September 2023, according to IQVIA.

FPJ Web DeskUpdated: Thursday, November 30, 2023, 11:33 AM IST
article-image
Aurobindo Pharma Subsidiary Eugia Pharma Receives USFDA Approval For Budesonide Inhalation Suspension | Image: Aurobindo Pharma (Representative)

Aurobindo Pharma Limited on Thursday announced that its wholly owned subsidiary company, Eugia Pharma Specialities Limited, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule, which is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), PULMICORT RESPULES® (budesonide) Inhalation Suspension by Astrazeneca Pharmaceuticals LP, the company announced through an exchange filing.

The product is expected to be launched in FY25. The approved product has an estimated market size of US dollar 226.4 million for the twelve months ending September 2023, according to IQVIA.

This is the 173rd ANDA approval (including 9 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oral and sterile specialty products.

Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampule is indicated for maintenance treatment of asthma and as prophylactic therapy in children of age 12 months to 8 years.

Aurobindo Pharma Limited shares

The shares of Aurobindo Pharma Limited on Thursday at 11:30 am IST were trading at Rs 1,039.40, up by 1.76 percent.

RECENT STORIES

Earnings March 2024: Anand Rathi Wealth Sees a 33% Jump In Its Profit

Earnings March 2024: Anand Rathi Wealth Sees a 33% Jump In Its Profit

Commercial AC Market Has Significant Growth Potential, Says President Of Appliance Makers' Body

Commercial AC Market Has Significant Growth Potential, Says President Of Appliance Makers' Body

Affordability In Peril? Share of Affordable Homes, Priced Up To ₹45 Lakh, Shrinks In Jan-Mar:...

Affordability In Peril? Share of Affordable Homes, Priced Up To ₹45 Lakh, Shrinks In Jan-Mar:...

Tech Earnings: After TCS, Infosys And Wipro To Release Results

Tech Earnings: After TCS, Infosys And Wipro To Release Results

Automobile Exports From India Dip 5.5% In FY24

Automobile Exports From India Dip 5.5% In FY24